Welcome to our dedicated page for THERALASE TECHS news (Ticker: TLTFF), a resource for investors and traders seeking the latest updates and insights on THERALASE TECHS stock.
Theralase Technologies Inc. reports company developments as a clinical-stage pharmaceutical developer of energy-activated small molecules for the destruction of cancer, bacteria and viruses. Its updates center on Ruvidar® (TLD-1433), including clinical and regulatory disclosures tied to non-muscle invasive bladder cancer and research into antiviral mechanisms such as HSV-1 inactivation.
Recurring announcements also cover operating and financial results, non-brokered private placements, line-of-credit financing, capital-structure disclosure, governance matters and development collaborations. The company’s news commonly links research progress with funding needs, regulatory pathways, intellectual-property considerations and commercialization risks for its small-molecule drug formulations.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Theralase Technologies Inc. (TSXV: TLT, OTCQB: TLTFF) has released its audited annual financial statements for 2022. The company experienced a 46% increase in total revenue to $1.14 million, fueled by recovery from the COVID-19 pandemic. Gross margin rose to 55% of revenue, compared to 40% in 2021. Selling and administrative expenses declined by 17% and 18%, respectively. However, net research and development expenses surged 46% to $4.28 million, resulting in a net loss of $5.24 million for the year. The company continues to progress in its Phase II clinical study for NMIBC treatments, reporting interim data indicating a 54% complete response rate at 90 days. Theralase was also recognized in the 2023 Venture 50™ for its performance in the Clean Technology and Life Sciences sector.
Theralase Technologies Inc. (OTCQB: TLTFF) announced promising interim results from its Phase II clinical study targeting BCG-Unresponsive, Non-Muscle Invasive Bladder Cancer (NMIBC). The study assesses TLD-1433 (Ruvidar™), a ruthenium-based drug activated by a proprietary laser device. Preliminary findings indicate a 53% complete response rate at 90 days, and a 28% rate at 450 days. These results suggest Ruvidar™ could be a viable, safer alternative to current therapies. The study aims to enroll up to 125 patients across 20 sites in Canada and the U.S. CEO Arkady Mandel noted the drug's potential to significantly impact treatment standards.